GSK's Herpes Simplex Virus Vaccine Fails to Meet Efficacy Endpoint in Phase II Trial

▎Armstrong

On September 11, 2024, GSK announced that the phase II clinical data analysis of the HSV vaccine showed it did not meet the primary endpoint. GSK will not proceed to phase III clinical trials but will continue to complete the follow-up and analysis of phase II clinical safety data.

GSK3943104 is a therapeutic HSV vaccine. The primary endpoint of its Phase II clinical trial was efficacy, indicating that this Phase II clinical trial did not meet the efficacy endpoint.

The

The

Of

The

Summary

Moderna is also focusing on the development of an HSV vaccine. The global infection rate of HSV-2 among adults is 13%, which is the leading cause of genital herpes, with approximately 178 million patients worldwide.